Maroxim

Dronabinol and Cannabidiol, the active ingredients in Maroxim, are cannabinoids presented as a blended inhalation formulation for inhalation use. It is used to manage nausea, stimulate appetite, and provide analgesia in adult patients where conventional therapy is insufficient.

GNH USA supplies Maroxim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maroxim combines dronabinol and cannabidiol and is employed in conditions where modulation of the endocannabinoid system can provide therapeutic benefit.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea episodes. - HIV/AIDS‑related weight loss: stimulates appetite and promotes weight gain. - Chronic pain: offers analgesic relief in patients with refractory pain.

Maroxim may cause a range of adverse reactions, most of which are related to its cannabinoid activity.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Dry mouth: reduced salivation leading to throat discomfort. - Fatigue: feeling unusually tired or weak. - Somnolence: increased sleepiness, especially after dosing. - Changes in appetite: either increased or decreased food intake. - Mild hypotension: slight drop in blood pressure causing faintness.

Serious or Rare Side Effects: - Severe hypotension: marked blood‑pressure decline requiring medical attention. - Psychosis or hallucinations: altered perception or mental status changes. - Respiratory depression: reduced breathing effort, particularly with high inhaled doses. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Cannabinoid hyperemesis syndrome: recurrent vomiting episodes. - Seizures: rare neurologic events, especially in predisposed individuals.

When prescribing Maroxim, clinicians should consider several safety aspects.

- Pregnancy: safety not established; avoid use unless benefits outweigh risks. - Respiratory disorders: use caution in patients with COPD or asthma. - Concomitant CNS depressants: monitor for additive sedation or respiratory effects. - History of psychosis: avoid or use with close supervision. - Driving and machinery: advise patients not to operate vehicles or heavy equipment while impaired. - Store at ambient temperature: keep in original container, protect from moisture and light.

Maroxim can interact with other medicines through metabolic pathways and central nervous system effects.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - CNS depressants (e.g., benzodiazepines, opioids): risk of profound sedation or respiratory depression. - Alcohol: enhances central effects and may impair coordination.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Antihypertensives: additive hypotensive effect, monitor blood pressure. - Other cannabinoids or CBD products: may increase side‑effect burden.